- Ext. (85) 16594
- About Head
Cardiovascular research program is among the newly launched strategic R&D focus areas at KAIMRC. The concept of the Cardiovascular research program, similar to other strategic R&D programs, is to bring in a coordinated and well integrated fashion a set of focused R&D projects bridging basic and clinical research. It also aims to strengthen translational research with an ultimate goal to develop personalized and precision medicine for cardiovascular diseases. Some of the major focus areas include Ischemic Heart Diseases, Congestive Heart Failure, pediatric cardiology and cardiac surgery. The main objective of the program is to enhance the capacity building in cardiovascular research throughout the academic medical center and to encourage and incentivize clinicians to conduct competitive and innovative research.
One of the main focuses of the program is to investigate coronary artery disease across its spectrum including prevention, detection, and advanced therapies. Investigators in the program are exploring multiple clinical, operational and behavioral tools in the primary and secondary prevention of coronary artery disease. In addition, investigators are utilizing advanced cardiac imaging for the early detection of coronary disease like cardiac positron emission tomography and coronary CT angiography in symptomatic patients and asymptomatic subjects. In addition, the role of new technologies in the cath lab and operating rooms like iFR is being investigated by clinical researchers. Clinical research activities in pediatric cardiology focused primarily on cardiovascular imaging, pediatric cardiovascular interventions, pulmonary hypertension and outcome research related to our active pediatric cardiac surgery program.
There are many ongoing clinical projects in the program including multicenter randomized controlled trials and investigator initiated studies. These include the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, THIEMS trial (A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus) and FLAIR study (Functional Lesion Assessment of Intermediate stenosis to guide Revascularization
Randomized Comparison of iFR to FFR). In addition, the investigators participate in multiple international registries like the ACC, STS and ESC registries